The selectivity of TRAIL in killing cancer cells promoted multiple clinical trials to evaluate the potential antitumor activity of recombinant human TRAIL (e.g. dulanermin) and agonistic antibodies to DR4 (e.g. mapatumumab) or DR5 (e.g. lexatumumab, AMG 655, PRO95780, LBY135, and CS-1008) [2, 8, 9]. Here, TNFSF10 is linked to cancer.